SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors react to its new NFL partnership, with some questioning the long-term impact and target audience fit, while others see potential for growth, especially with college-aged women. Community members are actively debating the significance of the deal and the company's overall direction, as well as the impact of analyst ratings. There's also discussion around potential manipulation and short squeezes in the stock.

Trump For President

TRUMP CRYPTO is trending amid mixed community sentiment, with some users labeling it a "scam" or "grift," while others express bullish sentiment. The coin's connection to Donald Trump and broader meme coin speculation appear to be key discussion points. Community members are actively discussing the coin's potential and whether it can displace other meme coins.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending due to the unveiling of new AI chips aimed at challenging Nvidia in the data center market, sparking a significant rally. The community is focused on the potential impact of these chips, particularly the AI200 and AI250, and whether this move signifies a long-term shift for the company beyond mobile chips. However, some analysts remain skeptical about the revenue potential and competitive edge of these chips, leading to a debate about whether the surge is justified.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to discussions around a potential acquisition deal falling through, leading to price volatility. The community is debating the implications of this failed deal, particularly regarding the company's future prospects and potential government support, in light of its position in the antimony market amid ongoing concerns about supply chain independence from China. Traders are also actively discussing technical analysis, potential entry points, and the stock's overall long-term value.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending due to a pause in two Phase 3 trials of its gene-editing therapy, nex-z, following a patient hospitalization with liver problems, causing a significant stock drop. The community is debating the severity of the setback, with some viewing it as a buying opportunity due to the company's long-term potential and strong pipeline, while others express concern about the program's future. Discussions also include the impact on the broader gene-editing sector and comparisons to similar situations with other companies.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending due to increasing interest in uranium and rare earth elements, particularly after securing a joint venture in Australia; the community is closely watching for potential government contracts and how the company will leverage its unique processing capabilities. Discussions revolve around the stock's volatile price action, recent call option activity, and its potential to benefit from geopolitical tensions and the push for resource independence. Some investors express concerns over short-term pullbacks after recent gains while others maintain a bullish long-term outlook, citing the company's strong fundamentals.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in the AI revolution, particularly highlighting its network infrastructure and a recent expansion of its Internet On-Demand service. Community members are weighing in on the company's prospects, with many focused on upcoming earnings and potential government contracts. There's considerable discussion around Lumen's Palantir partnership and speculation about further upside.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending as the company prepares to report earnings, with options activity suggesting a significant price swing is expected. Community members are actively discussing potential revenue growth and cost-cutting initiatives, with some drawing comparisons to meme stock rallies while others express skepticism based on past performance and cash burn.

NextEra Energy, Inc. engages in the provision of renewable energy. It operates through the following segments: FPL and NEER. The FPL segment involves the generation, transmission, distribution, and sale of electric energy in Florida. The NEER segment produces electricity from clean and renewable sources, including wind and solar. The company was founded on December 28, 1925 and is headquartered in Juno Beach, FL.

NextEra Energy Inc

NextEra Energy is trending amid news of a partnership with Google to restart a nuclear power plant, sparking community discussion about the growing energy demands of data centers and the potential for nuclear and renewables.  The company is also being compared favorably to sector peers, with some analysts citing stronger earnings estimates and ROE. Some investors are closely watching Q3 earnings and a strong setup heading into them.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as community members rally around the project's mission and IRL partnerships, including its sponsored MMA fighter Karolina Arm. The community emphasizes that $SLAP is more than just a meme; it's a lifestyle and brand focused on excellence. Discussions highlight the staking rewards and ongoing developments that differentiate it from other meme coins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

H.C. Wainwright⬆️ $MAZE $50/said, Yesterday, Maze&#39;s Phase 1 HV data from the MZE782, a SLC6A19 small molecule inhibitor program, showed a robust PD signal, far exceeding JNT-517&#39;s PD benchmark ( $OTSKY; Not rated) in HVs, reinforcing best-in-class potential of &#39;782 in PKU, in our opinion. 
 
However, the major surprise was the data from an exploratory analysis showing a dose dependent, 
reversible eGFR dip, indicating for the first time that MZE782 might play a therapeutic role in CKD similar to the SGLT2 inhibitors, in our opinion. 
 
Based on the KOL feedback we think that the eGFR dip pattern is consistent with a benign hemodynamic mechanism seen in ACEi/ARB/SGLT2i but believe that Phase 2 must confirm this with injury biomarkers and link it to proteinuria/UACR reduction. 
 
Therefore, given the compelling PoC data that now potentially supports efficacy in both PKU and CKD, we have increased our PoS assumptions for both the programs which increases our PT from $34 to $50. 
 
$AGIO BMRN $PTCT $TVTX

Leerink⬆️ $MAZE PT to $34 from $28, reit&#39;d at an OP/said MZE782 data exceeded its expys/support a pot&#39;l best-in-class profile. 
&amp; 
BTIG⬆️the PT on $MAZE to $37 from $30, reit&#39;d Buy/said, Phase 1 HV data of MZE782 reported today exceeded expectations and support best-in-class potential, showing urinary Phe excretion increases of 39-fold with a 960mg single dose and 42-fold with 240mg BID (mgmt. previously guided to &gt;10-fold and &gt;15-fold increases in PKU and CKD, respectively). 
$AGIO $BMRN $PTCT $TVTX  
BTIG went on to say:

StockTwits Web

Maze Therapeutics Inc.

Agios Pharmaceuticals Inc

Biomarin Pharmaceutical Inc. - Registered Shares

PTC Therapeutics Inc

Travere Therapeutics Inc

Quantumup

H.C. Wainwright reiterated $MAZE Buy/$50 
$VRTX $UNCY $OTSKY 
HCW said in its note to investors: We continue to believe that the next wave of kidney disease innovation will be defined by therapies that can demonstrate clinically meaningful proteinuria reductions and supportive eGFR trends in genetically enriched populations, with regulatory acceptance of these measures as surrogate endpoints. Towards that, we think Maze&#39;s MZE829 is uniquely positioned as the leading APOL1 targeted therapy, directly aligned with the recent PARASOL initiative and Rosenberg et al.&#39;s validation of proteinuria and slope as predictors of kidney failure. 
 
With no approved therapies for APOL1 kidney disease and Vertex as the only major competitor, we believe Maze is undervalued at current levels, and that Phase 2 data in Q1 2026 could serve as the inflection point for accelerated approval narratives and a significant upside for the stock. We reiterate our Buy rating and our price target of $50.

$AGIO $MAZE  and Leerink has sucked as bad as wainwright, with both these companies !!! Get that fact out too !!! BUTT BOY BEHRENS

StockTwits for iOS

Jose volvi

$AGIO   This is here why ??? Wainwright called $98 on AGIO in JULY 2021 only to see $16.95 in February 2022 , under the Fouse Fcuk up Regime !!! 
So wainwright is toast,here !!!

 $50/said, Yesterday, Maze's Phase 1 HV data from the MZE782, a SLC6A19 small molecule inhibitor program, showed a robust PD signal, far exceeding JNT-517's PD benchmark ( $OTSKY; Not rated) in HVs, reinforcing best-in-class potential of '782 in PKU, in our opinion. 
 
However, the major surprise was the data from an exploratory analysis showing a dose dependent, 
reversible eGFR dip, indicating for the first time that MZE782 might play a therapeutic role in CKD similar to the SGLT2 inhibitors, in our opinion. 
 
Based on the KOL feedback we think that the eGFR dip pattern is consistent with a benign hemodynamic mechanism seen in ACEi/ARB/SGLT2i but believe that Phase 2 must confirm this with injury biomarkers and link it to proteinuria/UACR reduction. 
 
Therefore, given the compelling PoC data that now potentially supports efficacy in both PKU and CKD, we have increased our PoS assumptions for both the programs which increases our PT from $34 to $50. 
 
